Myeloperoxidase: an inflammatory enzyme for generating dysfunctional high density lipoprotein

被引:93
|
作者
Shao, Baohai
Oda, Michael N.
Oram, John F.
Heinecke, Jay W.
机构
[1] Univ Washington, Div Metab Endocrinol & Nutr, Dept Med, Seattle, WA 98195 USA
[2] Childrens Hosp, Oakland Res Inst, Oakland, CA 94609 USA
关键词
atherosclerosis; dysfunctional HDL; myeloperoxidase; oxidation; oxidative stress;
D O I
10.1097/01.hco.0000231402.87232.aa
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of review Evidence indicates that high density lipoprotein (HDL) is cardioprotective and that several mechanisms are involved. One important pathway is a membrane-associated ATP-binding cassette transporter, ABCA1, that clears cholesterol from macrophage foam cells. Anti-inflammatory and antioxidant properties also might contribute to HDL's ability to inhibit atherosclerosis. Recent findings Myeloperoxidase targets HDL for oxidation, raising the possibility that the enzyme provides a specific mechanism for generating dysfunctional HDL in humans. Myeloperoxidase-dependent oxidation of apolipoprotein A-I, the major protein in HDL, blocks HDL's ability to remove excess cholesterol from cells by the ABCA1 pathway. Analysis of mutated forms of apoA-I and oxidized apoA-I treated with methionine sulfoxide reductase implicate oxidation of specific tyrosine and methionine residues in impairing the ABCA1 transport activity of apoA-I. The crystal structure of lipid-free apoA-I suggests that such oxidative damage might disrupt negatively charged regions on the protein's surface or alter its remodeling, resulting in conformations that fail to interact with ABCA1. Summary Oxidation of HDL by myeloperoxidase may represent a specific molecular mechanism for converting the cardioprotective lipoprotein into a dysfunctional form, raising the possibility that the enzyme represents a potential therapeutic target for preventing vascular disease in humans. Moreover, oxidized HDL might prove useful as a blood marker for clinically significant cardiovascular disease in humans.
引用
收藏
页码:322 / 328
页数:7
相关论文
共 50 条
  • [31] Role of myeloperoxidase in the neutrophil-induced oxidation of low density lipoprotein as studied by myeloperoxidase-knockout mouse
    Noguchi, N
    Nakano, K
    Aratani, Y
    Koyama, H
    Kodama, T
    Niki, E
    JOURNAL OF BIOCHEMISTRY, 2000, 127 (06) : 971 - 976
  • [32] Hepatic paraoxonase 1 ameliorates dysfunctional high-density lipoprotein and atherosclerosis in scavenger receptor class B type I deficient mice
    Zhao, Xiao-Jie
    Liu, Liang-Chen
    Guo, Cui
    Shen, Wen-Wen
    Cao, Jia
    Du, Fen
    Wu, Dong-Fang
    Yu, Hong
    ANNALS OF TRANSLATIONAL MEDICINE, 2021, 9 (13)
  • [33] Salutary Effects of Hemodialysis on Low-Density Lipoprotein Proinflammatory and High-Density Lipoprotein Anti-inflammatory Properties in Patient With End-Stage Renal Disease
    Vaziri, Nosratola D.
    Navab, Kaveh
    Gollapudi, Pavan
    Moradi, Hamid
    Pahl, Madeleine V.
    Barton, Cyril H.
    Fogelman, Alan M.
    Navab, Mohamad
    JOURNAL OF THE NATIONAL MEDICAL ASSOCIATION, 2011, 103 (06) : 524 - 533
  • [34] Evidence for an exclusive association of matrix metalloproteinase-9 with dysfunctional high-density lipoprotein: A novel finding
    Sini, S.
    Deepa, D.
    Harikrishnan, S.
    Jayakumari, N.
    ATHEROSCLEROSIS, 2014, 236 (01) : 162 - 168
  • [35] Entire Peroxidation Reaction System of Myeloperoxidase Correlates with Progressive Low-Density Lipoprotein Modifications via Reactive Aldehydes in Atherosclerotic Patients with Hypertension
    Liu, Quan
    Liu, Yawen
    Shi, Jikang
    Gao, Ming
    Liu, Yunkai
    Cong, Yetong
    Li, Yong
    Wang, Yonggang
    Yu, Mingxi
    Lu, Yuping
    Wang, Dahai
    Chen, Shan
    Zheng, Yang
    Cheng, Yi
    CELLULAR PHYSIOLOGY AND BIOCHEMISTRY, 2018, 50 (04) : 1245 - 1254
  • [36] Symmetric dimethylarginine in dysfunctional high-density lipoprotein mediates endothelial glycocalyx breakdown in chronic kidney disease
    Hesse, Bettina
    Rovas, Alexandros
    Buscher, Konrad
    Kusche-Vihrog, Kristina
    Brand, Marcus
    Di Marco, Giovana Seno
    Kielstein, Jan T.
    Pavenstaedt, Hermann
    Linke, Wolfgang A.
    Nofer, Jerzy-Roch
    Kuempers, Philipp
    Lukasz, Alexander
    KIDNEY INTERNATIONAL, 2020, 97 (03) : 502 - 515
  • [37] Comparative reactivity of the myeloperoxidase-derived oxidants HOCl and HOSCN with low-density lipoprotein (LDL): Implications for foam cell formation in atherosclerosis
    Ismael, Fahd O.
    Proudfoot, Julie M.
    Brown, Bronwyn E.
    van Reyk, David M.
    Croft, Kevin D.
    Davies, Michael J.
    Hawkins, Clare L.
    ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS, 2015, 573 : 40 - 51
  • [38] Comparison of HOCl traps with myeloperoxidase inhibitors in prevention of low density lipoprotein oxidation
    Jerlich, A
    Fritz, G
    Kharrazi, H
    Hammel, M
    Tschabuschnig, S
    Glatter, O
    Schaur, RJ
    BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY, 2000, 1481 (01): : 109 - 118
  • [39] Myeloperoxidase-derived oxidants modify apolipoprotein A-I and generate dysfunctional high-density lipoproteins: comparison of hypothiocyanous acid (HOSCN) with hypochlorous acid (HOCI)
    Hadfield, Katrina A.
    Pattison, David I.
    Brown, Bronwyn E.
    Hou, Liming
    Rye, Kerry-Anne
    Davies, Michael J.
    Hawkins, Clare L.
    BIOCHEMICAL JOURNAL, 2013, 449 : 531 - 542
  • [40] Correlation of low-density lipoprotein modification by myeloperoxidase with hypochlorous acid formation
    Jerlich, A
    Horakova, L
    Fabjan, JS
    Giessauf, A
    Jürgens, G
    Schaur, RJ
    INTERNATIONAL JOURNAL OF CLINICAL & LABORATORY RESEARCH, 1999, 29 (04) : 155 - 161